CIK 0001750149 · Non-accelerated filer<br>Smaller reporting company
Inhibikase Therapeutics, Inc.
Sign in to watch- Ticker
- IKT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 263407249
- Phone
- (302) 295-3800
- Business address
- 1000 N. WEST STREET, SUITE 1200, WILMINGTON, DE, 19801
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-30 | Munshi Amit Director | Grant or award · Stock Option (Right to Buy) | +108,176 | 108,176 | ||
| 2025-06-30 | Kush Arvind Director | Grant or award · Stock Option (Right to Buy) | +108,176 | 108,176 | ||
| 2025-06-30 | BERMAN DENNIS N Director | Grant or award · Stock Option (Right to Buy) | +108,176 | 108,176 | ||
| 2025-06-30 | Bellini Roberto Director | Grant or award · Stock Option (Right to Buy) | +108,176 | 108,176 | ||
| 2025-04-14 | McIntyre David Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +1,775,539 | 1,775,539 | ||
| 2025-02-21 | Munshi Amit Director | Grant or award | +57,265 | 57,265 | ||
| 2025-02-21 | Cabell Christopher President & Head of R&D | Grant or award · Stock Option (Right to Buy) | +1,100,705 | 1,100,705 | ||
| 2025-02-21 | Iwicki Mark T Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +602,346 | 602,346 | ||
| 2025-02-21 | Aurentz Vincent Director | Grant or award · Stock Option (Right to Buy) | +134,427 | 134,427 | ||
| 2025-02-21 | Cabell Christopher President & Head of R&D | Grant or award · Stock Option (Right to Buy) | +1,100,705 | 1,100,705 | ||
| 2025-02-21 | Aurentz Vincent Director | Grant or award · Stock Option (Right to Buy) | +134,427 | 134,427 | ||
| 2025-02-21 | Iwicki Mark T Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +602,346 | 602,346 | ||
| 2025-02-17 | Iwicki Mark T Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +1,794,291 | 1,794,291 | ||
| 2025-02-14 | Iwicki Mark T Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +4,373,857 | 4,373,857 | ||
| 2025-02-14 | Kush Arvind Director | Grant or award · Stock Option (Right to Buy) | +56,600 | 56,600 | ||
| 2025-02-14 | Kush Arvind Director | Grant or award · Stock Option (Right to Buy) | +116,585 | 116,585 | ||
| 2025-02-14 | Bellini Roberto Director | Grant or award · Stock Option (Right to Buy) | +73,580 | 73,580 | ||
| 2025-02-14 | Bellini Roberto Director | Grant or award · Stock Option (Right to Buy) | +116,585 | 116,585 | ||
| 2025-02-14 | Freeman Roy Lester Director | Grant or award · Stock Option (Right to Buy) | +22,640 | 22,640 | ||
| 2025-02-14 | Munshi Amit Director | Grant or award · Stock Option (Right to Buy) | +56,600 | 56,600 |
Page 2 of 9 · 163 trades